18F-FDG PET/CT Metabolic Response With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Treated With Cyclin-Dependent 4/6 Kinase Inhibitors

Dysregulation of the cyclin D–CDK4/6–INK4–RB pathway, which leads to uncontrolled cell proliferation, is frequently observed in breast cancer. Recently, 3 CDK4/6 inhibitors have been FDA approved as first-line treatment for patients with hormone receptor–positive, human epidermal growth factor recep...

Full description

Saved in:
Bibliographic Details
Published in:Clinical nuclear medicine 2022-09, Vol.47 (9), p.e605-e606
Main Authors: Filizoglu, Nuh, Ozguven, Salih, Erdil, Tanju Yusuf
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dysregulation of the cyclin D–CDK4/6–INK4–RB pathway, which leads to uncontrolled cell proliferation, is frequently observed in breast cancer. Recently, 3 CDK4/6 inhibitors have been FDA approved as first-line treatment for patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer. Despite promising clinical results, the metabolic response to treatment with these new drugs has not been elaborately demonstrated yet. Herein, we presented a patient with hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer who demonstrated a complete metabolic response on 18 F-FDG PET/CT to treatment with a CDK4/6 inhibitor (ribociclib).
ISSN:0363-9762
1536-0229
DOI:10.1097/RLU.0000000000004177